News & media

The latest news about Watrium
Oslo Atrium outside building
15 January 2018
New restauranteur at Oslo Atrium

Watrium has contracted 4Service’s subsidiary De 3 Stuer to operate the staff restaurant at Oslo Atrium in Bjørvika, Oslo, Norway.

Woman working in lab - Ultimovacs AS, Image: Charlotte Sverdrup
23 October 2017

Watrium has doubled its shareholding in Ultimovacs, a pharmaceutical company developing novel immunotherapy against cancer, through a private placement. For more information, see the press release from Ultimovacs (Norwegian only). Ultimovacs AS, Image: Charlotte Sverdrup

Product journey for Kezzler
16 October 2017

Watrium invests in Kezzler AS, a global leader in serialisation technologies.

Robot arm from Versius
18 September 2017

Watrium invests in Cambridge Medical Robotics Ltd, a private company developing a next-generation robotic system for universal minimal access surgery.

Orange Paracet pill box
24 August 2017
Watrium pre-accepts offer for Weifa shares

Watrium has pre-accepted Karo Pharma’s offer of NOK 35 per share for the 4 716 282 shares held in Weifa ASA.

To menn som håndhilser
22 April 2017
Watrium contracts Hent

Watrium has contracted the entrepreneur Hent AS to build A14, a new, Watrium-owned commercial real estate property in Bjørvika in Oslo. The six-floor building will cover a total of 4,300 square metres. For more information, see article at (in Norwegian only). Til venstre markedssjef i HENT Øyvind Kvarme og til høyre daglig leder for...

A hand reaching for a mini helicopter
30 November 2016

Watrium has sold its shares in Norwegian drone producer Prox Dynamics to American company FLIR Systems. The purchase price for 100 percent of the shares in Prox Dynamics was USD 134 million. For more information, see article in Teknisk Ukeblad (Norwegian only).

Fondbygget front of building
05 September 2016
Watrium divests sections at Aker Brygge

Watrium has entered into an agreement to sell sections in Fondsbygget at Aker Brygge in Oslo to Norwegian Property. The sections comprise approximately 3,200 square meters, mainly retail space on the ground floor. The closing of the transaction will take place in September 2016, and the agreed purchase price is NOK 204 million net of...

Ultimovacs logo
19 August 2016

Watrium invests to become a shareholder of Ultimovacs, a pharmaceutical company developing novel immunotherapy against cancer. Its leading product is UV1, a therapeutic cancer vaccine directed against human telomerase. Watrium’s Kristin Wilhelmsen also joins the company’s board of directors. For more information, see the Ultimovacs website.